AI-Native Scoping Reviews & Evidence Mapping

This SAIMSARA review maps 261 original studies comparing AVF and AVG for hemodialysis access, showing where fistulas dominate on durability, infection, mortality, and cost — and where grafts may be clinically preferable for frail, catheter-dependent, or poor-vein patients. The full evidence map gives humans and LLMs a structured, reference-linked view of patency, complications, survival, economics, patient subgroups, and access-selection trade-offs — ready for clinical reading, reasoning, and machine-readable evidence use.

Whiskey is not simply “alcohol in a glass”: this review maps a striking split between oak-derived congeners with measurable antioxidant, metabolic, and gastroprotective signals, and clear ethanol-related risks including arrhythmia, mucosal injury, pregnancy-related developmental harm, and upper aerodigestive cancer. The full paper is worth reading because it separates biomarker-level promise from clinically relevant harm, showing where whiskey differs mechanistically from beer or wine — and where those differences still do not prove real-world health benefit.

This review shows that vitamin D supplementation is far more than a simple deficiency fix: across a massive evidence base, its strongest signals emerge in targeted settings such as respiratory infection prevention, pregnancy, prediabetes, and selected inflammatory conditions, while many popular broad claims remain far less certain. The full paper is worth reading because it separates where vitamin D truly appears clinically meaningful from where biochemical repletion does not reliably translate into real-world benefit.

Postoperative complications in vascular surgery are not a single risk — they are a procedure-specific spectrum dominated by cardiac injury, wound/groin infection, renal dysfunction, pulmonary failure, and post-discharge events. This review maps where the danger concentrates and why generic risk calculators are insufficient for modern vascular practice.

This paper shows that people in urban areas now usually live longer and spend more years in good health, but the gap is not fixed and seems to depend on cardiovascular risk, injuries, deprivation, and access to care. The full paper is worth reading because it shows where the urban advantage is strongest, where rural populations still do better, and which health system failures most likely drive the difference.

TEVAR is no longer just a less invasive alternative to open repair — across type B dissection, traumatic injury, and thoracic aneurysm, it has become a strategy whose success depends on timing, landing-zone judgment, branch preservation, and complication control. This review shows where TEVAR clearly wins, where the evidence is still conflicted, and which technical decisions most strongly shape survival, remodeling, and long-term failure.

This review shows that TCAR is not just another carotid stenting technique, but a potentially safer endovascular strategy with a recurrent signal for lower stroke and death risk than transfemoral CAS, especially when neuroprotection matters most. The full read is worth it because it clarifies where that advantage looks strongest, where the evidence is still mixed, and which anatomical, symptomatic, and restenotic subgroups may truly benefit from TCAR.

This review shows that tattooing is far more than cosmetic ink: it maps how tattoos can act as long-term biological exposures linked to inflammation, pigment migration, diagnostic confusion, allergic disease, and possible cancer signals, while also serving as powerful medical tools in reconstruction, localization, drug delivery, and wearable sensing. The full paper is worth reading because it turns a scattered and emotionally charged topic into a clinically useful evidence map of where tattooing helps, where it harms, and which risks, technologies, and unanswered questions matter most.

This paper shows where systematic reviews and scoping reviews truly diverge: one is built to answer narrow, bias-sensitive questions, the other to map broad, uncertain evidence landscapes. Read the full text to see how reporting quality, automation, rapid reviews, overviews, and emerging synthesis methods fit into one practical framework for choosing the right review design.

This review shows that chronic pain is not only a symptom burden, but a clinically important suicide-risk context shaped by depression, sleep disturbance, mental defeat, catastrophizing, opioid transitions, and functional loss. The full read is worth it because it maps exactly which pain populations and care settings carry the strongest signal, where the evidence is most consistent, and which modifiable targets may help move suicide prevention in pain care from intuition to strategy.

Statins are not just cholesterol drugs: across an enormous evidence base, this review shows how they may help protect healthspan and longevity by lowering recurrent vascular events and mortality, while also exposing the real trade-offs around diabetes risk, intolerance, and poor long-term adherence. The full paper is worth reading because it separates where statins most clearly extend durable cardiovascular protection from where the evidence becomes mixed, controversial, and potentially relevant to broader aging-related pathways such as inflammation, liver disease, and neurocognitive decline.

This paper shows that statins remain one of the strongest cardiovascular therapies, consistently linked to fewer major events and lower mortality across very large populations, but not without trade-offs such as diabetes risk, muscle symptoms, and rises in lipoprotein(a). The full paper is worth reading because it shows where the benefit is most convincing, where the risks matter most, and how to think more clearly about the real balance between protection and harm.